A review of the current management and burden of prurigo nodularis in the United States.

Autor: Chisolm SS; Emory University, 1525 Clifton Rd. NE, 1st floor, Atlanta, GA 30322. Email: Sarah.chisolm@emory.edu.
Jazyk: angličtina
Zdroj: The American journal of managed care [Am J Manag Care] 2023 May; Vol. 29 (5 Suppl), pp. S63-S72.
DOI: 10.37765/ajmc.2023.89366
Abstrakt: Prurigo nodularis (PN) is a chronic neural- and immune-mediated disease that is characterized by intense itch, history of skin scratching, and development of papulonodular lesions. These lesions can develop consequent to a cycle of itching and scratching associated with inflammation and changes in skin cells and nerve fibers (eg, pathogenic skin fibrosis, tissue remodeling, and chronic neuronal sensitization). Diagnosis of PN involves individual evaluation of clinical characteristics to identify disease and symptom severity. In the United States, adult patients with PN (estimated, < 90,000) are more likely to be older (age, 50-60 years); in addition, this disease is detected at higher rates in women and Black individuals relative to other demographic subgroups. Still, the small population of patients with PN exhibits considerably high use of health care resources and experiences considerable symptom burden and negatively impacted quality of life. Further, PN is associated with increased rates of a range of comorbid diseases compared with other inflammatory dermatoses (eg, atopic dermatitis, psoriasis). Adequate treatment must address both the neural and immunological component of the disease; there remains a great unmet need for safe and effective therapies that can reduce the burden of disease.
Databáze: MEDLINE